Back

Evaluation of appropriate use and clinical outcomes of idarucizumab as antidote of dabigatran in daily clinical practice

26 August 2018 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Atrial fibrillation - Stroke prevention Oral Anticoagulation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Mr Sake van der Wall

Onze Lieve Vrouwe Gasthuis, Haarlem (Netherlands (The))

10 More presentations in this session

Presentation thumbnail
Doctor X. Li (Princeton, US)
Abstract Slides
Presentation thumbnail
Associate Professor H. Yu (Seoul, KR)
Abstract
Presentation thumbnail
Doctor M. Esteve Pastor (Murcia, ES)
Abstract
Presentation thumbnail
Doctor Z. Salpagarova (Moscow, RU)
Abstract
Presentation thumbnail
Doctor S. Aeschbacher (Basel, CH)
Abstract

Access the full session

Session thumbnail
Poster Session 3 - Atrial fibrillation - Stroke prevention

The Event

Event poster

ESC Congress 2018

26 August 2018 14:00 CET
You may be interested in
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Presentation
State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope
thumbnail
Congress Session
Oral anticoagulation in subclinical atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources